The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
Open accessAbstract
Summary Background No standard treatments are available for advanced thymic epithelial tumours after failure of platinum-based chemotherapy. We investigated the activity of sunitinib, an orally administered tyrosine kinase inhibitor. Methods Between May 15, 2012, and Oct 2, 2013, we did an open-label phase 2 trial in patients with histologically confirmed chemotherapy-refractory thymic epithelial tumours. Patients were eligible if they had disease progression after at least one previous regimen of platinum-containing chemotherapy, an Eastern Cooperative Oncology Group performance status of two or lower, measurable disease, and adequate organ function. Patients received 50 mg of sunitinib orally once a day, in 6-week cycles (ie, 4 weeks of treatment followed by 2 weeks without treatment), until tumour progression or unacceptable toxic effects arose. The primary endpoint was investigator-assessed best tumour response at any point, which we analysed separately in thymoma and thymic carcinoma cohorts. Patients who had received at least one cycle of treatment and had their disease reassessed were included in the analyses of response. The trial was registered with ClinicalTrials.gov, number NCT01621568. Findings 41 patients were enrolled, 25 with thymic carcinoma and 16 with thymoma. One patient with thymic carcinoma was deemed ineligible after enrolment and did not receive protocol treatment. Of patients who received treatment, one individual with thymic carcinoma was not assessable because she died. Median follow-up on trial was 17 months (IQR 14·0–18·4). Of 23 assessable patients with thymic carcinoma, six (26%, 90% CI 12·1–45·3, 95% CI 10·2–48·4) had partial responses, 15 (65%, 95% CI 42·7–83·6) achieved stable disease, and two (9%, 1·1–28·0) had progressive disease. Of 16 patients with thymoma, one (6%, 95% CI 0·2–30·2) had a partial response, 12 (75%, 47·6–92·7) had stable disease, and three (19%, 4·1–45·7) had progressive disease. The most common grade 3 and 4 treatment-related adverse events were lymphocytopenia (eight [20%] of 40 patients), fatigue (eight [20%]), and oral mucositis (eight [20%]). Five (13%) patients had decreases in left-ventricular ejection fraction, of which three (8%) were grade 3 events. Three (8%) patients died during treatment, including one individual who died of cardiac arrest that was possibly treatment-related. Interpretation Sunitinib is active in previously treated patients with thymic carcinoma. Further studies are needed to identify potential biomarkers of activity. Funding National Cancer Institute (Cancer Therapy Evaluation Program).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
Haber, D. A., & Velculescu, V. E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1014 · Cited by 694
Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis
Gao, D., Nolan, D. J., Mellick, A. S., Bambino, K., McDonnell, K., & Mittal, V. (2008) · Science · doi:10.1126/science.1150224 · Cited by 632
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
Engels, E. A., & Pfeiffer, R. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11099 · Cited by 500
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors
Petrini, I., Meltzer, P. S., Kim, I.-K., Lucchi, M., Park, K.-S., Fontanini, G., Gao, J., Zucali, P. A., Calabrese, F., Favaretto, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3016 · Cited by 255
Self-citation
Cited by
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx, A., Chan, J. K. C., Coindre, J.-M., Detterbeck, F., Girard, N., Harris, N. L., Jaffe, E. S., Kurrer, M. O., Marom, E. M., Moreira, A. L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000654 · Cited by 603
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giaccone, G., Kim, C., Thompson, J., McGuire, C., Kallakury, B., Chahine, J. J., Manning, M., Mogg, R., Blumenschein, W. M., Tan, M. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30062-7 · Cited by 408
Self-citationThe Integrated Genomic Landscape of Thymic Epithelial Tumors
Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., Hoadley, K. A., Anur, P., Zhang, J., McLellan, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.003 · Cited by 381
Self-citationCho, J., Kim, H. S., Ku, B. M., Choi, Y.-L., Cristescu, R., Han, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3184 · Cited by 344
Self-citationKarzai, F., VanderWeele, D., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., Couvillon, A., Nichols, E., Bilusic, M., Beshiri, M. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0463-2 · Cited by 309
Self-citation
Metadata
- Authors
- Thomas, A., Rajan, A., Berman, A., Tomita, Y., Brzezniak, C., Lee, M.-J., Lee, S., Ling, A., Spittler, A. J., Carter, C. A., Guha, U., Wang, Y., Szabo, E., Meltzer, P., Steinberg, S. M., Trepel, J. B., Loehrer, P. J., & Giaccone, G.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 16
- Issue
- 2
- Pages
- 177-186
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2168558240
- Cited by
- 304
- References
- 17
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71181-7
- The paper
- Thomas, A., Rajan, A., Berman, A., Tomita, Y., Brzezniak, C., Lee, M.-J., Lee, S., Ling, A., Spittler, A. J., Carter, C. A., Guha, U., Wang, Y., Szabo, E., Meltzer, P., Steinberg, S. M., Trepel, J. B., Loehrer, P. J., & Giaccone, G. (2015). Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71181-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.